Strata Oncology Announces Medicare Coverage of StrataNGS Comprehensive Genomic Profiling Test for Patients with Advanced Solid Tumors
Large-Scale Study Shows Guardant360 Liquid Biopsy Accelerates Clinical Trial Enrollment Compared to Tissue Biopsy
Guardant Health Guardant360® CDx First FDA-Approved Liquid Biopsy for Comprehensive Tumor Mutation Profiling Across All Solid Cancers
Mike Pellini, Section 32: “I hope we will find a way where the payers and the healthcare industry will work much more closely together to generate the data that will ultimately be useful in answering difficult, cost-based decisions.”
The Life of a Genetic Counselor: Providing Patient Education, Navigating Insurance, and Challenges in Choosing Tests